Access to anti-retroviral drugs, female in Lithuania

Lithuania: Access to anti-retroviral drugs, female was 56.0% in 2024. ◆ Volatile

Latest (2024)
56.0%
Change on year
up 9.8%
World rank
110th
of 141 countries
All-time high
56.0%
in 2024
All-time low
0.0%
in 2000
Years of data
25
2000–2024

Access to anti-retroviral drugs, female in Lithuania, 2000–2024

02040602000201220242000: 0 %2001: 0 %2002: 0 %2003: 1 %2004: 2 %2005: 2 %2006: 3 %2007: 4 %2008: 5 %2009: 6 %2010: 7 %2011: 8 %2012: 11 %2013: 20 %2014: 15 %2015: 22 %2016: 25 %2017: 27 %2018: 35 %2019: 37 %2020: 38 %2021: 39 %2022: 45 %2023: 51 %2024: 56 %

Source: UNAIDS estimates. Measured in %.

Analysis

In 2024, access to anti-retroviral drugs, female in Lithuania stood at 56.0%. That is the highest value across all 25 years on record.

That represents a change of up 9.8% on the previous year and up 273.3% over ten years.

Over the whole period, access to anti-retroviral drugs, female in Lithuania peaked at 56.0% in 2024 and was at its lowest, 0.0%, in 2000.

Lithuania ranks 110th of 141 countries on this measure, in the bottom quarter.

The series is highly variable year to year, so single readings are best treated with caution.

Access to anti-retroviral drugs, female in Lithuania, year by year

Annual values for Access to anti-retroviral drugs, female (%) in Lithuania, 2000 to 2024.
Year % Change
2000 0.0%
2001 0.0%
2002 0.0%
2003 1.0%
2004 2.0% +100.0%
2005 2.0% +0.0%
2006 3.0% +50.0%
2007 4.0% +33.3%
2008 5.0% +25.0%
2009 6.0% +20.0%
2010 7.0% +16.7%
2011 8.0% +14.3%
2012 11.0% +37.5%
2013 20.0% +81.8%
2014 15.0% -25.0%
2015 22.0% +46.7%
2016 25.0% +13.6%
2017 27.0% +8.0%
2018 35.0% +29.6%
2019 37.0% +5.7%
2020 38.0% +2.7%
2021 39.0% +2.6%
2022 45.0% +15.4%
2023 51.0% +13.3%
2024 56.0% +9.8%

Averages by decade

DecadeAverage LowestHighest Years
2000s 2.3% 0.0% 6.0% 10
2010s 20.7% 7.0% 37.0% 10
2020s 45.8% 38.0% 56.0% 5

Countries ranked near Lithuania

  1. 108 Greece 57.0% compare
  2. 108 Timor-Leste 57.0% compare
  3. 111 Gambia 55.0% compare
  4. 111 Panama 55.0% compare
  5. 111 Paraguay 55.0% compare

See the full ranking of 160 places →

More gender data for Lithuania

All data for Lithuania →

Frequently asked questions

What is access to anti-retroviral drugs, female in Lithuania?
Access to anti-retroviral drugs, female in Lithuania was 56.0% in 2024, according to UNAIDS estimates.
What is the highest access to anti-retroviral drugs, female recorded in Lithuania?
The highest recorded value was 56.0% in 2024.
What is the lowest access to anti-retroviral drugs, female recorded in Lithuania?
The lowest recorded value was 0.0% in 2000.
How does Lithuania rank for access to anti-retroviral drugs, female?
Lithuania ranks 110th out of 141 countries with data for 2024.
Is access to anti-retroviral drugs, female rising or falling in Lithuania?
Over the last ten years it is up 273.3%. The long-run trend across the full record is volatile.
Where does this Lithuania data come from?
The figures come from UNAIDS estimates, published as part of Access to anti-retroviral drugs, female (%). Statizoid updates them automatically from the source API.

Download this data

CSV · JSON — 25 observations, free to reuse under CC BY 4.0 (World Bank Open Data).

Share, cite or embed this page

Cite this page

Access to anti-retroviral drugs, female in Lithuania. Statizoid, drawing on UNAIDS estimates. Retrieved 06 September 2026, from https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-female-percent/lithuania/

Embed or link this data

Paste this into a page to link back to these figures. The data itself is free to reuse under CC BY 4.0 (World Bank Open Data); please keep the attribution.

<a href="https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-female-percent/lithuania/">Access to anti-retroviral drugs, female in Lithuania</a> — Statizoid

About this data

Indicator
Access to anti-retroviral drugs, female (%)
Unit
%
Source
UNAIDS estimates
Licence
CC BY 4.0 (World Bank Open Data)
Coverage
160 places, 3,925 data points, 2000–2024
Last refreshed

The percentage of adult females living with HIV who are receiving antiretroviral therapy.